obesity treatment

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY 09/27/2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies.

Clinical Updates Wellness & Lifestyle

SANA: A Novel Nitroalkene Salicylate Derivative Promoting Creatine-Dependent Thermogenesis and Weight Loss

By MedXY 09/17/2025

SANA, a nitroalkene derivative of salicylate, enhances creatine-dependent thermogenesis to reduce obesity and improve metabolic health, showing promising safety and efficacy in preclinical and early clinical studies.

Clinical Updates Wellness & Lifestyle

Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity

By MedXY 09/17/2025

Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.

Clinical Updates Wellness & Lifestyle

Advancing Obesity Management: Once-Monthly Maridebart Cafraglutide Demonstrates Significant Weight Loss Efficacy

By MedXY 09/07/2025

Maridebart cafraglutide, a novel once-monthly peptide-antibody conjugate, significantly reduces body weight in individuals with obesity, with and without type 2 diabetes, offering a new therapeutic option based on phase 2 trial results.

Clinical Updates Wellness & Lifestyle

Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena

By MedXY 08/17/2025

Eli Lilly's oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying, promising diverse mechanisms and potential market shifts.